Abstract | BACKGROUND: AIM: To compare the efficacy of three regimens containing ranitidine bismuth citrate given for 1, 2 and 4 weeks, combined with two antibiotics for the first week, in the eradication of H. pylori. METHODS: RESULTS: Overall, H. pylori was eradicated in 84% (72/86) patients on intention-to-treat analysis, whereas the per protocol cure rate was 89% (72/81). Eradication rates were 23/27 (85%) (95% confidence interval (CI): 66-96%), 25/27 (92%) (95% CI: 76-99%) and 24/27 (89%) (95% CI: 71-98%) in the 1-, 2- and 4-week groups, respectively, on per protocol analysis, and 25/28 (82%) (95% CI: 63-94%), 25/29 (86%) (95% CI: 68-96%) and 24/29 (83%) (95% CI: 64-94%), respectively, on intention-to-treat analysis (P > 0.05, N.S.). No significant differences were observed between groups concerning duodenal ulcer healing, resolution of symptoms and adverse effects. CONCLUSIONS:
|
Authors | D Kamberoglou, D Polymeros, I Sanidas, V Doulgeroglou, S Savva, E Patra, V Tzias |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 15
Issue 9
Pg. 1493-7
(Sep 2001)
ISSN: 0269-2813 [Print] England |
PMID | 11552924
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Anti-Ulcer Agents
- Metronidazole
- ranitidine bismuth citrate
- Ranitidine
- Clarithromycin
- Bismuth
|
Topics |
- Adult
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Anti-Ulcer Agents
(administration & dosage, therapeutic use)
- Bismuth
(administration & dosage, therapeutic use)
- Clarithromycin
(administration & dosage, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Duodenal Ulcer
(drug therapy, microbiology)
- Female
- Helicobacter Infections
(drug therapy)
- Helicobacter pylori
- Humans
- Male
- Metronidazole
(administration & dosage, therapeutic use)
- Middle Aged
- Ranitidine
(administration & dosage, analogs & derivatives, therapeutic use)
- Treatment Outcome
|